Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Genet Eng Biotechnol ; 21(1): 109, 2023 Nov 06.
Article in English | MEDLINE | ID: mdl-37930593

ABSTRACT

BACKGROUND: Obesity is one of the most serious problems over the world. MicroRNAs have developed as main mediators of metabolic processes, playing significant roles in physiological processes. Thus, the present study aimed to evaluate the expressions of (miR-15a, miR-Let7, miR-344, and miR-365) and its relationship with the different classes in obese patients. METHODS: A total of 125 individuals were enrolled in the study and classified into four groups: healthy non-obese controls (n = 50), obese class I (n = 24), obese class II (n = 17), and obese class III (n = 34) concerning body mass index (BMI < 30 kg/m2, BMI 30-34.9 kg/m2, BMI 35-39.9 kg/m2 and BMI ≥ 40 kg/m2, respectively). BMI and the biochemical measurements (fasting glucose, total cholesterol, triglycerides, HDL and LDL, urea, creatinine, AST, and ALT) were determined. The expressions of (miR-15a, miR-Let7, miR-344, and miR-365) were detected through quantitative real-time PCR (RT-qPCR). RESULTS: There was a significant difference between different obese classes and controls (P < 0.05) concerning (BMI, TC, TG, HDL, and LDL). In contrast, fasting glucose, kidney, and liver functions had no significant difference. Our data revealed that the expression of miR-15a and miR-365 were significantly associated with different obese classes. But the circulating miR-Let7 and miR-344 were not significantly related to obesity in different classes. CONCLUSION: Our study indicated that miR-15a and miR-365 might consider as biomarkers for the obesity development into different obese classes. Thus, the relationship between regulatory microRNAs and disease has been the object of intense investigation.

2.
Acta Pol Pharm ; 72(2): 307-18, 2015.
Article in English | MEDLINE | ID: mdl-26642681

ABSTRACT

New substituted triazolopyrimidne derivatives were synthesized starting from 1,2,3-triazolo-4-carboxamide derivative. The N- and S-glycoside derivatives of the synthesized triazolopyrimidine ring system as well as their acyclic sugar analogs were also synthesized. The cytotoxicity and in vito anticancer evaluation of the prepared compounds have been assessed against three different human tumor cell lines including human breast MCF-7, lung A549 and colon HCT116 cancer cell lines. The results revealed that the prepared compounds exert their actions in MCF-7 and A549. MCF-7 cells are more sensitive to the tested compounds than the other cell lines. Compounds 2, 3, 9 and 10 revealed promising anticancer activities compared to the activity of the commonly used anticancer drug, doxorubicin in both MCF-7 and A549 cell lines.


Subject(s)
Antineoplastic Agents/chemical synthesis , Nucleosides/chemical synthesis , Pyrimidines/chemical synthesis , Triazoles/chemical synthesis , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Doxorubicin/pharmacology , Humans , Nucleosides/pharmacology , Pyrimidines/pharmacology , Structure-Activity Relationship , Triazoles/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...